<DOC>
	<DOCNO>NCT02207439</DOCNO>
	<brief_summary>This Phase II trial definitive chemoradiotherapy ( CTRT ) give protease inhibitor , Nelfinavir ( NFV ) , patient locally advanced head neck . Eligible patient receive `` lead-in '' period Nelfinavir ( 1250 mg po bid ) 7-14 day prior initiation CTRT . Nelfinavir give concurrently platinum-based chemotherapy radiation therapy ( plan total dose 70 Gy 7 week ) .</brief_summary>
	<brief_title>A Phase II Trial Protease Inhibitor , Nelfinavir ( NFV ) , Given With Definitive , Concurrent Chemoradiotherapy ( CTRT ) Patients With Locally-Advanced , Human Papilloma Virus ( HPV ) Negative , Squamous Cell Carcinoma Larynx</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Patients ≥ 18 year old . Histologically confirm diagnosis squamous cell carcinoma oral cavity , oropharynx , larynx , hypopharynx stage III , IVa , IVb , p16negative immunohistochemistry Determined treat physician candidate organ preserve , concurrent standard chemotherapy radiation therapy head neck definitive intent . ECOG Performance Status 02 Patients must sign informed consent document indicate aware investigational nature treatment protocol well potential risk benefit . The effect EF5 develop human fetus unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry , study , 1 month completion final 18FEF5 PET/CT scan . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Serum pregnancy test required woman childbearing potential . Ability understand willingness sign write informed consent . Exclusion Criteria Prior radiation therapy head neck Prior chemotherapy within past 5 year Previous therapy human immunodeficiency virus ( HIV ) protease inhibitor Pregnant lactating patient . Patients know HIV disease . These patient high probability treatment antiretroviral therapy may interact nelfinavir . Absolute Neutrophil Count ≤ 1500 per mm3 Platelet count ≤ 100,000 per mm3 Serum creatinine &gt; 1.5 time upper limit normal Serum AST ALT &gt; 2 time upper limit normal Serum bilirubin &gt; 1.2 mg/dl Weight loss &gt; 10 % past 6 month due tumor waste syndrome Distant metastases Patients receive follow drug contraindicate NFV exclude : Antiarrhythmics : amiodarone , quinidine , Antimycobacterial : rifampin , Ergot Derivatives : dihydroergotamine , ergonovine , ergotamine , methylergonovine , Herbal Products : St.John 's wort ( hypericum perforatum ) , HMGCoA Reductase Inhibitors : lovastatin , simvastatin , Neuroleptic : pimozide , Proton Pump Inhibitors , Sedative/Hypnotics : midazolam , triazolam , Patients receive follow drug clinically evaluate whether dosage/medication change permit patient study : AntiConvulsants : carbamazepine , Phenobarbital , AntiConvulsant : phenytoin , AntiMycobacterial : rifabutin , PDE5 Inhibitors : sildenafil , vardenafil , tadalafil , HMGCoA : Reductase Inhibitors : atorvastatin , rosuvastatin , Immunosuppressants : cyclosporine , tacrolimus , sirolimus , Narcotic Analgesic : methadone , Oral Contraceptive : ethinyl estradiol , Macrolide Antibiotic : azithromycin , Inhaled/nasal steroid fluticasone , Antidepressant : trazodone . Women childbearing potential positive result screen urine pregnancy test . Subjects moderatesevere renal disease . History allergic reactionsattributed Flagyl ( metronidazole ) , chemical structure similar EF5 . Uncontrolled intercurrent illness include , limited symptomatic congestive heart failure , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>